TargetGag-Pol polyprotein(Human immunodeficiency virus type 1 (HIV-1))
Critical Outcome Technologies
US Patent
Critical Outcome Technologies
US Patent
Affinity DataIC50: 1.40E+4nMAssay Description:The effect of each compound on HIV integrase activity was assayed using the HIV-1 Integrase Assay Kit version 2.0, catalogue number EZ-1700 obtained ...More data for this Ligand-Target Pair
TargetGag-Pol polyprotein(Human immunodeficiency virus type 1 (HIV-1))
Critical Outcome Technologies
US Patent
Critical Outcome Technologies
US Patent
Affinity DataIC50: 2.39E+4nMAssay Description:The effect of each compound on HIV integrase activity was assayed using the HIV-1 Integrase Assay Kit version 2.0, catalogue number EZ-1700 obtained ...More data for this Ligand-Target Pair
TargetGag-Pol polyprotein(Human immunodeficiency virus type 1 (HIV-1))
Critical Outcome Technologies
US Patent
Critical Outcome Technologies
US Patent
Affinity DataIC50: 5.87E+4nMAssay Description:The effect of each compound on HIV integrase activity was assayed using the HIV-1 Integrase Assay Kit version 2.0, catalogue number EZ-1700 obtained ...More data for this Ligand-Target Pair